BridgeMD
New treatment option for Advanced Endometrial Cancer
Official title Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
ClinicalTrials.gov ID: NCT06584032
What this study is testing
What is fruquintinib?
fruquintinib is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for advanced endometrial cancer.
Also referred to as HMPL-013.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this study is to evaluate whether fruquintinib(HMPL-013) plus sintilimab(IBI308) is safe and effective in the treatment of advanced endometrial cancer(EMC).
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75, women only
You may be able to join if
- Have fully understood and voluntarily signed the informed consent form
- Age 18 to 75 years (inclusive) ; Body mass index (BMI) ≥ 18.5kg/m\^2;
- Histologically or cytologically confirmed advanced or recurrent endometrial cancer with measurable lesions
- Patients who previously failed first-line systemic platinum-based therapy
- ECOG PS (Eastern Cooperative Oncology Group performance status score) 0 or 1;
You likely can't join if
- Endometrial carcinosarcoma or sarcoma;
- Known MMR(mismatch repair)/MSI status with dMMR(deficient mismatch repair) or MSI-H(microsatellite instability-high);
- Toxicities related to prior anticancer therapy did not recover to ≤CTCAE Grade 1, except alopecia and oxaliplatin-induced peripheral neurotoxicity...
- Received systemic anti-tumor therapy approved within 4 weeks before randomization;
- Other malignancies within the past 5 years;
- Previous or screening central nervous system (CNS) metastases;
See the full eligibility criteria
- Have fully understood and voluntarily signed the informed consent form
- Age 18 to 75 years (inclusive) ; Body mass index (BMI) ≥ 18.5kg/m\^2;
- Histologically or cytologically confirmed advanced or recurrent endometrial cancer with measurable lesions
- Patients who previously failed first-line systemic platinum-based therapy
- ECOG PS (Eastern Cooperative Oncology Group performance status score) 0 or 1;
- Need to provide tumor samples for central lab testing of biomarkers such as MSI(microsatellite instability) status;
- Non-MSI-H(non-microsatellite instability-high) by central lab or previous test result indicating pMMR(proficient mismatch repair);
- Adequate function of the major organs;
- Expected survival ≥ 12 weeks;
- Female patients of childbearing potential must have a negative serum pregnancy test within 7 days before randomization.
- Endometrial carcinosarcoma or sarcoma;
- Known MMR(mismatch repair)/MSI status with dMMR(deficient mismatch repair) or MSI-H(microsatellite instability-high);
- Toxicities related to prior anticancer therapy did not recover to ≤CTCAE Grade 1, except alopecia and oxaliplatin-induced peripheral neurotoxicity ≤CTCAE Grade 2;
- Received systemic anti-tumor therapy approved within 4 weeks before randomization;
- Other malignancies within the past 5 years;
- Previous or screening central nervous system (CNS) metastases;
- Radical radiotherapy within 4 weeks before randomization
- Previously received any anti-programmed cell death receptor-1 (PD-1) antibody, anti-PD-L1(programmed death ligand-1) antibody, anti-PD-L2(programmed death ligand-2) antibody, or anti cytotoxic T lymphocyte-associated...
- Symptomatic or treatment-requiring thyroid dysfunction at screening;
- Use of immunosuppressive agents within 4 weeks before randomization
- Presence of any active autoimmune disease requiring systemic treatment or history of autoimmune disease within the past 2 years;
- Systemic immunostimulants within 4 weeks before randomization;
- Administration of any live or live-attenuated vaccine within 4 weeks before randomization or planned during the study;
- Major surgical procedures within 4 weeks before randomization;
- Uncontrolled malignant pleural effusion, ascites or pericardial effusion;
- Patients with current hypertension uncontrolled by medication;
- Patients with any current disease or condition affecting drug absorption, or patients unable to take oral medications;
- Receiving strong inducers of cytochrome P450 3A4 enzyme;
- Patients with gastrointestinal diseases or unresected tumors with active bleeding, or other conditions that may cause gastrointestinal bleeding and perforation as judged by the investigator; or with gastrointestinal...
- Active bleeding within 3 weeks before randomization, or melena, or bleeding from a tumor within 2 weeks before the first dose ;
- Tumor invading major vascular structures and is judged by the investigator to be at greater risk of massive haemorrhage;
- Patients who had arterial thrombosis or deep venous thrombosis within 6 months before randomization; or patients who had stroke events and/or transient ischemic attack within 12 months; patients who had thrombosis...
- Clinically significant cardiovascular disease;
- Clinically significant electrolyte abnormalities as judged by the investigator;
- Active infection or fever of unknown origin before randomization;
- Patients with active pulmonary tuberculosis (TB) receiving anti-tuberculosis treatment or anti-tuberculosis treatment within 1 year before randomization;
- Patients with previous and current history of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, severely impaired pulmonary function, which may interfere with the...
- Positive human immunodeficiency virus (HIV) antibody screening;
- Known history of clinically significant liver disease
- Known hypersensitivity to any of the study drugs or any of their excipients, or previous history of serious hypersensitivity to any other monoclonal antibody;
- Patients who have received other clinical drugs that have not been approved or marketed within 4 weeks before randomization;
- Women who are pregnant (positive pregnancy test before medication) or breastfeeding;
- Patients who have received tissue/organ transplantation;
- Patients with known psychiatric disorders or substance abuse disorders that could affect study compliance;
- Patients who, in the opinion of the investigator, have other reasons that would make them inappropriate for this clinical study.
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, Beijing Municipality, China
- Chongqing, Chongqing Municipality, China
- Fuzhou, Fujian, China
- Guangzhou, Guangdong, China
- Nanning, Guangxi, China
- Harbin, Heilongjiang, China
- Zhengzhou, Henan, China
- Changsha, Hunan, China
- Xi'an, Shaanxi, China
- Jinan, Shandong, China
- Shanghai, Shanghai Municipality, China
- Taiyuan, Shanxi, China
- Tianjin, Tianjin Municipality, China
- Kunming, Yunnan, China
- Hangzhou, Zhejiang, China
- Wenzhou, Zhejiang, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, Beijing Municipality, China; Chongqing, Chongqing Municipality, China; Fuzhou, Fujian, China; Guangzhou, Guangdong, China; Nanning, Guangxi, China; Harbin, Heilongjiang, China and 10 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.